EF Hutton Assumes VolitionRX at Buy, Announces Price Target of $6
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler assumes coverage of VolitionRX (AMEX:VNRX) with a Buy rating and announces a price target of $6.
June 01, 2023 | 8:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tony Butler initiates coverage on VolitionRX with a Buy rating and a price target of $6.
The Buy rating and price target announcement by EF Hutton analyst Tony Butler is likely to have a positive short-term impact on VolitionRX's stock price. Investors may see this as a sign of confidence in the company's potential and could drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100